Who
Janeen Noel Doyle
Chief Corp. & Bus. Dev. Ofcr
Company insider
Files Form 4 as: Chief Corp. & Bus. Dev. Ofcr, Janux Therapeutics.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $114K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 2 Jun 2025
- Last trade
- 2 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Jun – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Jun 2026filed 4 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K4,059 at $14.03 | filing |
| 2 Jun 2026filed 4 Jun 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $57K4,059 at $14.03 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —126,000 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —126,000 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —154,000 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
News
Janux Therapeutics (NASDAQ:JANX) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Head-To-Head AnalysisJANX · themarketsdaily.com · 24 Oct 2026Reviewing Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV)JANX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Janeen Noel Doyle; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.